Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.41 |
| ▸ | KDR | P35968 | 7/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.32 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30555523 | 1.00 | KDM4C (0.41) | KDM4CKDRGRM4CYP11B1CYP11B2 | |
| SCHEMBL23248496 | 0.91 | KDM4C (0.39) | KDM4CKDRGRM4CYP11B1CYP11B2 | |
| SCHEMBL30555510 | 0.91 | KDM4C (0.39) | KDM4CKDRGRM4CYP11B1CYP11B2 | |
| SCHEMBL30555530 | 0.88 | GRM4 (0.38) | KDM4CKDRGRM4MAP3K5 | |
| SCHEMBL26120831 | 0.88 | GRM4 (0.38) | KDM4CKDRGRM4MAP3K5 | |
| SCHEMBL30555427 | 0.87 | KDM4C (0.39) | KDM4CKDRP2RX7MAP3K5 | |
| SCHEMBL26120408 | 0.87 | KDM4C (0.39) | KDM4CKDRP2RX7MAP3K5 | |
| SCHEMBL30555465 | 0.87 | P2RX7 (0.34) | KDM4CCYP11B1CYP11B2TGFBR1LRRK2 | |
| SCHEMBL30555460 | 0.87 | KDM4C (0.33) | KDM4CCYP11B1CYP11B2TGFBR1LRRK2 | |
| SCHEMBL26122403 | 0.87 | P2RX7 (0.34) | KDM4CCYP11B1CYP11B2TGFBR1LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358879-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-07-15 | — | — | US | disclosed |
| EP-4046688-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2025-04-09 | — | — | EP | disclosed |
| US-20230322683-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-12 | — | — | US | disclosed |
| US-20230322683-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-12 | — | — | US | disclosed |
| US-20230322683-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-12 | — | — | US | disclosed |
| EP-4046688-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2022-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322683-A1 | HETEROCYCLIC COMPOUND | PARK7, SMN1; SMN2, SNCA | KDM4C 1231/4885KDR 4879/4885GRM4 1924/4885 |
| US-12358879-B2 | Heterocyclic compound | PARK7, SMN1; SMN2, SNCA | KDM4C 1231/4885KDR 4879/4885GRM4 1924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.